QLi5 Therapeutics
Next Generation Proteasome inhibitors for unmet medical needs deployed by an international Research & Development Network
Next Generation Proteasome Inhibitors
A new class of proteasome inhibitors with a unprecedented, non-covalent mode of action has been developed in close collaboration with Prof. Robert Huber from the Max Planck Institute for Biochemistry.
QLi5 compounds should allow application in wide range of application due to
Platform Technology for unmet medical needs
QLi5 Compounds show strong anti-tumor activity against multiple myeloma and solid tumors.
